On Nov 09, major Wall Street analysts update their ratings for $Evolent Health (EVH.US)$, with price targets ranging from $27 to $63.
Barclays analyst Stephanie Davis maintains with a buy rating, and maintains the target price at $39.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and maintains the target price at $63.
Oppenheimer analyst Michael Wiederhorn maintains with a buy rating, and adjusts the target price from $45 to $34.
BTIG analyst David Larsen maintains with a buy rating, and adjusts the target price from $45 to $36.
JMP Securities analyst Constantine Davides maintains with a buy rating, and adjusts the target price from $43 to $27.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
Evolent Health's Q3 EBITDA was notably lower than the consensus, primarily due to a marked rise in Oncology costs, both retrospective and within the quarter. On a positive note, the company secured $200M in new run-rate business during Q3, underscoring the increased demand for specialty care management.
Evolent Health's Q3 outcomes were described as below expectations. Previously, it appeared that the company was on course to offset rising costs through contractual rate increases. Despite this, the recent stock selloff implies skepticism among investors about the company's ability to achieve approximately $300M in EBITDA. Nonetheless, the belief is that the recent circumstances are atypical and that Evolent's margins will return to normal as the rate increases are implemented.
Here are the latest investment ratings and price targets for $Evolent Health (EVH.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
